Brief: Immunovant Provides Update On Graves' Disease Development Program

Immunovant

09/09/2024 08:57

Sept 9 (Reuters) - Immunovant Inc  IMVT.O :
    * IMMUNOVANT PROVIDES UPDATE ON GRAVES’ DISEASE DEVELOPMENT PROGRAM
    * IMMUNOVANT INC - HIGH DOSE BATOCLIMAB ACHIEVES 76% RESPONSE RATE IN
UNCONTROLLED
ATD PATIENTS
    * IMMUNOVANT INC - HIGH DOSE BATOCLIMAB ACHIEVES 56% ATD-FREE RESPONSE RATE
    * IMMUNOVANT INC - IND CLEARED FOR IMVT-1402 PIVOTAL TRIAL IN GD EXPECTED BY
YEAR-END

Source text for Eikon:  ID:nGNX5lZdPT 
Further company coverage:  IMVT.O 

 ((Reuters.Briefs@thomsonreuters.com;;))